Shots:
- The EC has approved Usymro (BAT2206), a biosimilar version of J&J’s Stelara (ustekinumab) for all indications of the reference product
- In Oct 2024, Bio-Thera & Gedeon Richter entered a licensing & commercialization deal under which Bio-Thera will develop & manufacture Usymro, while Gedeon will commercialize it post-approval & MA Holder transfer in the EU, UK, & Switzerland
- Ustekinumab is a fully human anti-IL-12/IL-23 mAb indicated for the treatment of autoimmune diseases incl. plaque psoriasis, psoriatic arthritis & Crohn’s disease
Ref: PRNewswire | Image: Bio-Thera | Press Release
Related News:- Bio-Thera Solutions Expands its Partnership with STADA for BAT1806 (Biosimilar, RoActemra)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
